Microglia, the resident immune cells of the central nervous system, have exhibited dualistic behaviors in the context of AD. On one hand, they facilitate the clearance of toxic amyloid-β (Aβ) plaques, a hallmark of AD, through phagocytosis. Yet, with aging, these protective capabilities tend to decline. As aging progresses, research indicates a paradoxical enhancement of microglial phagocytosis concerning synapses and neurons, which may contribute to neurodegenerative processes that potentially accelerate the onset of cognitive decline and atrophy.

One of the significant discoveries in the realm of genetic risk factors for AD is the correlation between many known genetic variants and microglial activity. Genes such as APOD, ABI3, and TREM2, among others, are intricately tied to the functioning of microglial cells. These genetic factors pose a compelling connection between the innate immune response and neurodegenerative pathology. It illustrates how variations in these genes might influence the efficiency of phagocytic mechanisms, thus affecting an individual’s susceptibility to AD.

The interplay of these genes with microglial phagocytosis provides compelling evidence of their role in the accumulation and clearance of Aβ aggregates. In this context, anti-Aβ therapies, primarily monoclonal antibodies designed to enhance microglial phagocytosis, have emerged as potential interventions to alter the disease trajectory. By stimulating the innate immune response through these antibodies, researchers aim to facilitate the clearance of Aβ plaques, hoping to mitigate pathology and improve cognitive outcomes for individuals with AD.

Yet, the narrative is not entirely straightforward. Microglial phagocytosis, while essential in early stages of disease management, takes on a more sinister role as AD progresses. Certain pathways activated during phagocytosis might become maladaptive, particularly involving the complement system and Tau pathology. Research suggests that during advanced stages of AD, microglia inadvertently contribute to neurodegeneration by excessively removing synapses and promoting inflammation rather than healing—a switch from a protective phenotype to a harmful one.

Additionally, the dynamics of microglial activation can further complicate interpretations of their roles in AD. Microglia can exhibit distinct phenotypic states, influenced by various environmental cues, including cytokines and cellular stressors. This plasticity may determine whether microglia facilitate repair processes or contribute to exacerbated neuronal loss. Understanding how microglia transition between these states during the disease continuum is paramount for developing targeted therapies.

The emerging involvement of immune mechanisms—particularly TREM2 and APOE genotypes—introduces a layer of complexity regarding microglial functionality in AD. TREM2, a receptor that expedites the clearance of Aβ, has displayed a pivotal role in regulating microglial responses to damage. Variants in the TREM2 gene have been linked to increased risk of AD, underscoring its importance in microglial phagocytic activity. Similarly, the APOE ε4 allele has become notorious for its strong association with AD risk, highlighting how microglial interactions influence amyloid plaque metabolism and corresponding inflammatory responses.

As research delves deeper into the nuances of microglial phagocytosis, potential therapeutic avenues may unfold. An improved understanding of the conditions that bolster beneficial microglial activities, while curbing detrimental ones, could pave the way for innovative strategies aimed at restoring homeostasis in neuroinflammatory responses. It may require a multifaceted approach that encompasses pharmacological interventions, lifestyle modifications, and strategies focusing on environmental factors contributing to microglial health.

One promising line of investigation involves small molecule modulators that can finely tune microglial activity, balancing their phagocytic functions. These compounds hold the promise to inhibit harmful pathways while enhancing beneficial responses, potentially creating a therapeutic window for AD patients. Optimizing the timing of interventions to coincide with critical periods of synaptic development or degeneration might further enhance their efficacy.

Furthermore, leveraging neuroinflammation as a therapeutic target presents an attractive option for modulating AD progression. As the scientific community continues to unearth the complexities associated with microglial activity over the lifecycle of AD, understanding how to harness or moderate these responses could revolutionize the treatment landscape. Such approaches would allow for a more nuanced understanding of the relationships between microglial phagocytosis, neurodegeneration, and cognitive decline.

As the search for disease-modifying therapies for AD intensifies, the dialogue around microglial function and phagocytosis remains central. Dissecting these pathways will be instrumental for the ingenuity required to tackle one of modern medicine’s most perplexing challenges. With each new discovery, new questions arise, yet the central premise becomes clearer: microglial phagocytosis or the lack thereof, may hold the key to unlocking effective interventions against Alzheimer’s disease.

The clamor for a nuanced understanding of microglial roles in AD is palpable, echoing through laboratories and research institutions worldwide. Scientists and clinicians alike are called to explore these avenues further, with the hope of translating novel insights into groundbreaking therapies capable of altering the trajectory of AD, ultimately improving outcomes for countless individuals affected by this debilitating condition. The promise of innovative treatments fueled by enhanced comprehension of microglial biology could herald a new era in the fight against neurodegenerative diseases, potentially changing the lives of millions in the process.

The engagement within the scientific community with regards to microglial phagocytosis, alongside the hope surrounding therapeutic advancements, accentuates the urgent need for continued research. With collaboration spanning various fields, from molecular biology to clinical trials, the acceleration towards unraveling the secrets of microglial mechanisms is critical. By nurturing the dialogue between genetic insights and therapeutic innovations, a brighter, more promising horizon for AD treatment can be envisioned—one in which individuals may thrive despite the challenges posed by this relentless disease.

Ultimately, a united front among researchers, clinicians, and laypersons about the importance of understanding microglial phagocytosis in the context of Alzheimer’s disease will foster the development of interventions built on a robust foundation of scientific inquiry. The fight against AD is far from over; rather, it is just beginning, and the answers resting within the complexities of microglial behavior may be the key to unlocking a future where this devastating condition is met with effective and transformative solutions.

Subject of Research: Microglial Phagocytosis in Alzheimer’s Disease

Article Title: Microglial phagocytosis in Alzheimer disease

Article References:

Brown, G.C., St George-Hyslop, P., Paolicelli, R.C. et al. Microglial phagocytosis in Alzheimer disease.
Nat Rev Neurol (2025). https://doi.org/10.1038/s41582-025-01162-y

Image Credits: AI Generated

DOI: 10.1038/s41582-025-01162-y

Keywords: Alzheimer’s disease, microglial phagocytosis, neuroinflammation, amyloid-β, TREM2, genetic risk, therapeutic interventions.

At the crux of the discovery lies the intricate role of microglia, the brain’s resident immune sentinels, whose functional states profoundly influence neuroinflammatory and neurodegenerative dynamics. Single-nucleus RNA sequencing (snRNA-seq) analyses revealed that lithium deficiency precipitates a marked decrease in microglial populations expressing Cx3cr1, a gene encoding a key homeostatic marker. Concurrently, there is an increase in microglia expressing Apoe, a gene intimately associated with AD risk. These transcriptional changes mirror the reactive microglial phenotype observed during AD progression, indicating lithium’s crucial role in maintaining microglial homeostasis.

To gain a more nuanced understanding of microglial alterations under lithium-deficient conditions, investigators isolated viable microglial cells from both transgenic 3xTg and wild-type mouse models. Deep RNA sequencing demonstrated profound transcriptome remodeling in microglia subjected to lithium deficiency, characterized by overlapping gene expression changes across both genetic backgrounds. Genes upregulated in lithium-deficient microglia clustered in pathways linked to Alzheimer’s and broader neurodegenerative processes, encompassing electron transport chain function, respiratory metabolism, amyloid fibril formation, translation, and oxidative stress responses.

Conversely, genes downregulated by lithium deficiency were enriched for biological processes critical to genomic and proteomic integrity, such as DNA damage responses, cellular stress adaptation, intracellular import mechanisms, and protein catabolism. This dichotomous gene regulation profile suggests that lithium shortage may impair essential microglial housekeeping functions while simultaneously exacerbating pathological activation, tipping the balance toward neurodegeneration.

Further analysis connected lithium deficiency-induced transcriptomic signatures to established genetic risk factors for Alzheimer’s disease identified through genome-wide association studies (GWAS). Notable risk genes such as Trem2, Bin1, Clu, Picalm, Cd33, HLA-DRB1 orthologue H2-Eb1, Inpp5d, Abca1, Abca7, and Adam10 were among those significantly enriched in lithium-deprived microglia. Strikingly, there was also a strong overlap with gene sets characteristic of microglia expressing glycoprotein NMB (GPNMB), a marker of microglial populations expanding during AD progression. Upregulation of GPNMB expression further validated the transition to a reactive and potentially neurotoxic microglial state under lithium-deficient conditions.

Immunohistochemical examination revealed that lithium deficiency robustly increased microglial activation markers. Specifically, the density of CD68-positive microglia—a hallmark of reactive, phagocytic microglia—was elevated in the hippocampi of 3xTg AD mice subjected to a lithium-deficient diet. This microglial activation was similarly noted in a separate AD mouse model (J20), underscoring the reproducibility and robustness of the phenomenon. The study also identified enhanced expression of microglial proteins GPNMB and lipoprotein lipase (LPL), both implicated in AD-associated microglial phenotypes, strengthening the link between lithium deficiency and microglial pathology.

Functionally, microglia isolated from lithium-deficient mice exhibited heightened pro-inflammatory responses when challenged ex vivo with lipopolysaccharide (LPS). These cells secreted elevated levels of classical pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor (TNF), and granulocyte-colony stimulating factor (G-CSF), alongside chemokines such as CCL3, CCL4, CCL5, and CXCL2. This cytokine milieu fosters a neurotoxic and inflammatory environment, which may potentiate neuronal dysfunction and amyloid pathology in the Alzheimer’s brain.

In addition to heightened inflammatory activity, lithium deficiency significantly impaired the microglial capacity for amyloid-beta 42 (Aβ42) peptide uptake and degradation. These functions are critical for clearing amyloid plaques, the classic pathological hallmark of AD. The diminished phagocytic and catabolic efficiency of microglia under lithium-deficient conditions aligns with a scenario wherein clearance of pathogenic protein aggregates is compromised, thus accelerating disease progression.

An intriguing mechanistic link tying these findings together involves glycogen synthase kinase 3 beta (GSK3β), a kinase known to modulate multiple aspects of neurodegeneration and inflammation. Immunolabelling demonstrated increased GSK3β levels in microglia from lithium-deficient mice. Pharmacological inhibition of GSK3β restored Aβ42 uptake and degradation capabilities in cultured microglia from lithium-deficient animals, highlighting GSK3β as a critical modulator in lithium’s regulation of microglial function and suggesting potential therapeutic targets.

The converging evidence from transcriptomics, immunohistochemistry, cytokine secretion profiles, and functional assays paints a comprehensive picture of lithium as a vital regulator of microglial state and activity. Lithium deficiency mobilizes microglia into a reactive, pro-inflammatory, and functionally compromised phenotype that mirrors features observed in Alzheimer’s disease, thus implicating systemic lithium status in AD pathogenesis.

These findings carry profound implications for public health and clinical strategies. Given the widespread prevalence of suboptimal lithium exposure in the general population, subtle lithium insufficiency could represent a modifiable risk factor accelerating neurodegeneration. The results prompt a reevaluation of nutritional and environmental lithium intake and its integration into preventive approaches targeting early stages of Alzheimer’s disease.

While lithium has been historically utilized in psychiatric medicine, primarily for bipolar disorder, this study rejuvenates interest in its neuroprotective properties and advocates for its further exploration as a potential disease-modifying agent in neurodegenerative diseases. Careful determination of optimal dosages and assessment of long-term safety profiles will be essential steps to harness lithium’s therapeutic potential fully.

This pioneering research adds a novel dimension to the complex landscape of Alzheimer’s pathology, bridging metabolic, inflammatory, and genetic factors through the common denominator of lithium status. As the global burden of Alzheimer’s continues to grow, these insights chart a promising course toward innovative, biologically grounded interventions that may delay or halt the progression of this devastating disorder.

In summary, lithium deficiency exerts a profound impact on microglial biology, driving transcriptional reprogramming toward a disease-associated state characterized by impaired amyloid clearance and amplified neuroinflammation. The link to key AD genetic risk pathways and functional impairments underscores lithium’s foundational role in brain homeostasis and neurodegenerative disease modulation. Further research will be essential to translate these compelling findings into clinical benefits for patients at risk of Alzheimer’s disease.

Subject of Research: Lithium deficiency and its impact on microglial activation and Alzheimer’s disease onset

Article Title: Lithium deficiency and the onset of Alzheimer’s disease

Article References:
Aron, L., Ngian, Z.K., Qiu, C. et al. Lithium deficiency and the onset of Alzheimer’s disease. Nature (2025). https://doi.org/10.1038/s41586-025-09335-x

Image Credits: AI Generated